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had died. The use of nimorazole improved the loco-regional 
tumour control with an 18 months post-randomisation 
cumulative failure rate of 31% versus 54% in the control 
group, yielding a risk difference of 23% (CI 2%-45%; P= 0.03). 
The corresponding values for overall death was 39% versus 
68%; risk difference 28% (CI 4%-52%; P= 0.02).  
Conclusions: Although the trial was incomplete and suffered 
from small and incomplete number of patients, did the 
analysis indicate a loco-regional control and survival benefit 
in patients given the hypoxic modifier nimorazole in addition 
to accelerated fractionation for advanced HNSCC. 
However, the trial also revealed that conducting multicenter 
and multinational clinical studies combining drug and 
radiotherapy in developing countries, may suffer from 
uncontrolled and unsolvable problems. 
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Purpose/Objective: Patients with incurable locally advanced 
non-small cell lung cancer (NSCLC) (mainly Stage IIIB) usually 
receive palliative treatment with either radiotherapy (RT) 
alone (39 Gy in 13 fractions or 10-17 Gy in 1-2 fractions) or 
several cycles of doublet chemotherapy (CHT) regimens. In 
order to optimize treatment approach in this disease and 
improve access to RT in limited resource setting, 
International Atomic Energy Agency conducted a prospective 
randomised study (NCT00864331) comparing protracted RT 
course with CHT followed by one or two fractions of RT. 
Materials and Methods: Total of 65 patients from 7 
institutions aged ≥ 18 years, with histologically confirmed 
NSCLC, stage IIIA/IIIB, Karnofsky performance status (KPS) 60-
90, previously not treated for NCSLC were randomised, 31 to 
arm A and 34 to arm B. Exclusion criteria were RT field > 200 
cm2 and pregnancy. In arm A, RT consisted of 39 Gy in 13 
fractions. In arm B, 2 to 3 platinum-based CHT cycles were 
prescribed, and were followed by 10 Gy given in a single 
fraction or 16 Gy given in 2 fractions separated by one week. 
Further treatments depended on disease progression and 
patient condition and were left to the discretion of involved 
radiation oncologist. Primary outcome was overall survival.  
Results: Treatment groups were balanced with respect to 
various variables (Table 1). Treatment compliance was also 
given in Table 1.  
 
With follow-up through Feb 2014, 6/65 remained alive, 3 in 
each arm (all 6 being lost to follow-up at > 1 yr of 
observation). Median survival for all 65 patients was 0.66 yr 
(maximum 5.0 yr), while median survival was 0.59 and 0.68 
yr for the two arms, respectively (log-rank p=0.4 by study 
arm, and p=0.6 by Cox regression, stratified by country and 
sub-stage). One- to three-year survival rates for the two arms 
were 29%, 9% and 9% vs 41%, 12% and 6%, respectively) 
(Figure 1). 
  
There was no difference in any of the following endpoints (all 
values, p>0.5): any failure, occurring in 26 cases each in A 
and B; local failure, occurring in 18 cases each; regional 
failure, occurring in 6 and 8 cases in the two arms, 
respectively; contra-lateral thoracic disease, occurring in 3 
cases each; and distant failure, occurring in 13 and 14 cases 
in the two arms, respectively. Post-initial treatment, in arm 
A more courses of palliative RT were administered (17 
courses in 11 cases, vs. 4 in 4 cases in arm B), along with 
slightly more palliative CHT cycles (19 cycles in 7 cases, vs. 
11 in 2 cases in arm B).  
Conclusions: There were no differences in survival, relapse 
patterns and symptoms between the two arms. When 
compared to high-dose palliative RT, CHT followed by one or 
two fractions of RT produced similar results. It can be 
recommended as treatment approach, especially in limited 
resource setting, where access to RT remains inadequate.  
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